Drug · FAERS side-effect profile with label screen

Cyclophosphamide For side effects: what 175,993 FDA adverse event reports show

Cyclophosphamide For Injection · 1,367 reaction terms · 561,290 drug–reaction co-reports · data 2026-09-14

Drug class

Alkylating drug

FDA label, Indications wording of the closest related product

Label matched

Cyclophosphamide For Injection (Cyclophosphamide)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

175,993 reports · 96% serious · 35,641 with death outcome · 55% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burk.

FDA label, Indications and Usage

What it is

Cyclophosphamide is a phosphorodiamide that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by two 2-chloroethyl groups at the amino nitrogen atom.

PubChem CID 2907 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 9Likely indication confounding 9Lab value / disease marker 1Not in label — unassessed 20

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,327 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Lymphoid tissue hypoplasia	139	2,025.4 993.2–4,130.4ROR 2,027.0 · calibrated p 3e-17 ✓	109.5 EB05 95.1 · IC025 +6.0 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=139 · ♀ 0% (drug 55%)	no trial arm names this drug
Thymus hypoplasia	140	544.0 366.7–806.9ROR 544.4 · calibrated p 2e-13 ✓	95.6 EB05 83.0 · IC025 +5.9 3/3 methods agree	Not in label — unassessed	serious n=140 · ♀ 0% (drug 55%)	no trial arm names this drug
Human bocavirus infection	116	187.8 140.0–252.0ROR 187.9 · calibrated p 1e-9 ✓	71.7 EB05 61.4 · IC025 +5.5 3/3 methods agree	Not in label — unassessed	serious n=116	no trial arm names this drug
Diffuse large b-cell lymphoma recurrent	1,247	166.5 152.7–181.5ROR 167.7 · calibrated p 2e-9 ✓	69.1 EB05 65.9 · IC025 +6.0 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=1,246 · 93% clinician	no trial arm names this drug
Cystitis viral	177	103.7 84.7–126.9ROR 103.8 · calibrated p 1e-7 ✓	55.0 EB05 48.6 · IC025 +5.3 3/3 methods agree	Labeled (related wording) related wording	serious n=174 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Mantle cell lymphoma recurrent	190	95.1 78.5–115.1ROR 95.2 · calibrated p 2e-7 ✓	52.5 EB05 46.6 · IC025 +5.3 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=190 · ♀ 30% (drug 55%) · 93% clinician	no trial arm names this drug
B-cell lymphoma recurrent	230	87.9 74.1–104.3ROR 88.0 · calibrated p 3e-7 ✓	50.3 EB05 45.1 · IC025 +5.3 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=230	no trial arm names this drug
Diffuse large b-cell lymphoma refractory	391	86.5 75.9–98.6ROR 86.7 · calibrated p 4e-7 ✓	50.0 EB05 45.9 · IC025 +5.4 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=391 · 91% clinician	no trial arm names this drug
Blood stem cell transplant failure	89	83.7 63.7–109.8ROR 83.7 · calibrated p 7e-7 ✓	48.6 EB05 40.7 · IC025 +4.9 3/3 methods agree	Labeled (related wording) related wording	serious n=88 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Viral haemorrhagic cystitis	284	80.2 68.9–93.2ROR 80.3 · calibrated p 6e-7 ✓	47.8 EB05 43.3 · IC025 +5.3 3/3 methods agree	Labeled (related wording) related wording	serious n=284 · 100% clinician	no trial arm names this drug
Engraftment syndrome	231	77.2 65.3–91.1ROR 77.3 · calibrated p 9e-7 ✓	46.7 EB05 41.8 · IC025 +5.2 3/3 methods agree	Not in label — unassessed	serious n=229 · ♀ 34% (drug 55%)	no trial arm names this drug
Primary amyloidosis	92	67.9 52.5–87.8ROR 67.9 · calibrated p 3e-6 ✓	42.9 EB05 36.0 · IC025 +4.8 3/3 methods agree	Not in label — unassessed	serious n=92 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Encephalitis cytomegalovirus	155	66.4 54.5–80.9ROR 66.5 · calibrated p 3e-6 ✓	42.5 EB05 37.1 · IC025 +5.0 3/3 methods agree	Not in label — unassessed	serious n=155 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Cytomegalovirus infection reactivation	1,352	55.1 51.6–58.8ROR 55.5 · calibrated p 7e-6 ✓	37.7 EB05 36.1 · IC025 +5.1 3/3 methods agree	Labeled (related wording) related wording	serious n=1,348 · 98% clinician	no trial arm names this drug
Acute graft versus host disease in skin	871	54.8 50.6–59.4ROR 55.1 · calibrated p 7e-6 ✓	37.6 EB05 35.5 · IC025 +5.1 3/3 methods agree	Not in label — unassessed	serious n=866 · 98% clinician	no trial arm names this drug
Acute graft versus host disease	1,426	53.1 49.9–56.5ROR 53.5 · calibrated p 9e-6 ✓	36.8 EB05 35.2 · IC025 +5.1 3/3 methods agree	Not in label — unassessed	serious n=1,418 · 96% clinician	no trial arm names this drug
Engraft failure	88	52.9 41.1–68.0ROR 52.9 · calibrated p 1e-5 ✓	36.4 EB05 30.5 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=87 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Follicular lymphoma	256	50.9 44.0–59.0ROR 51.0 · calibrated p 1e-5 ✓	35.7 EB05 32.1 · IC025 +4.9 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=251 · 93% clinician	no trial arm names this drug
Cystitis bacterial	100	49.4 39.1–62.4ROR 49.4 · calibrated p 2e-5 ✓	34.8 EB05 29.4 · IC025 +4.6 3/3 methods agree	Labeled (related wording) related wording	serious n=100	no trial arm names this drug
Congenital aplasia	85	49.3 38.3–63.5ROR 49.3 · calibrated p 2e-5 ✓	34.7 EB05 28.9 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=85 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Diffuse large b-cell lymphoma stage iv	94	48.7 38.3–62.0ROR 48.7 · calibrated p 2e-5 ✓	34.4 EB05 29.0 · IC025 +4.5 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=94 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Chronic graft versus host disease	1,056	48.5 45.2–52.1ROR 48.8 · calibrated p 2e-5 ✓	34.5 EB05 32.8 · IC025 +5.0 3/3 methods agree	Not in label — unassessed	serious n=1,054 · 97% clinician	no trial arm names this drug
Cystitis haemorrhagic	1,125	46.1 43.1–49.4ROR 46.4 · calibrated p 2e-5 ✓	33.3 EB05 31.7 · IC025 +4.9 3/3 methods agree	Labeled (related wording) related wording	serious n=1,120 · 95% clinician	no trial arm names this drug
Venoocclusive disease	700	46.0 42.1–50.2ROR 46.2 · calibrated p 2e-5 ✓	33.2 EB05 31.2 · IC025 +4.9 3/3 methods agree	Not in label — unassessed	serious n=695 · ♀ 34% (drug 55%) · 91% clinician	no trial arm names this drug
Norovirus test positive	90	45.6 35.8–58.2ROR 45.6 · calibrated p 3e-5 ✓	32.9 EB05 27.5 · IC025 +4.5 3/3 methods agree	Lab value / disease marker	serious n=90	no trial arm names this drug
Ovarian failure	143	42.7 35.3–51.8ROR 42.8 · calibrated p 4e-5 ✓	31.4 EB05 27.3 · IC025 +4.6 3/3 methods agree	Labeled adverse reaction exact term	serious n=141 · ♀ 100% (drug 55%) · 100% clinician	no trial arm names this drug
Disseminated aspergillosis	123	42.2 34.3–51.8ROR 42.2 · calibrated p 5e-5 ✓	31.1 EB05 26.8 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=123 · ♀ 0% (drug 55%)	no trial arm names this drug
Lymphoma transformation	94	41.8 33.0–52.9ROR 41.8 · calibrated p 5e-5 ✓	30.9 EB05 26.0 · IC025 +4.4 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=94 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Venoocclusive liver disease	1,273	41.4 38.9–44.2ROR 41.7 · calibrated p 4e-5 ✓	30.8 EB05 29.4 · IC025 +4.8 3/3 methods agree	Not in label — unassessed	serious n=1,262 · 96% clinician	no trial arm names this drug
Human polyomavirus infection	132	40.4 33.1–49.2ROR 40.4 · calibrated p 6e-5 ✓	30.1 EB05 26.1 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=130 · ♀ 0% (drug 55%) · 100% clinician	no trial arm names this drug
Human herpesvirus 6 infection	477	39.6 35.7–43.9ROR 39.7 · calibrated p 6e-5 ✓	29.8 EB05 27.6 · IC025 +4.7 3/3 methods agree	Not in label — unassessed	serious n=476 · 91% clinician	no trial arm names this drug
Acute graft versus host disease in liver	180	39.4 33.3–46.7ROR 39.5 · calibrated p 6e-5 ✓	29.6 EB05 26.2 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=179 · 95% clinician	no trial arm names this drug
Hepatitis b reactivation	791	39.3 36.3–42.6ROR 39.5 · calibrated p 6e-5 ✓	29.6 EB05 27.9 · IC025 +4.7 3/3 methods agree	Labeled (related wording) related wording	serious n=778 · 94% clinician	no trial arm names this drug
Acute graft versus host disease in intestine	348	39.1 34.6–44.2ROR 39.2 · calibrated p 6e-5 ✓	29.5 EB05 27.0 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=347 · 100% clinician	no trial arm names this drug
Graft versus host disease in skin	543	38.8 35.2–42.8ROR 38.9 · calibrated p 6e-5 ✓	29.4 EB05 27.3 · IC025 +4.7 3/3 methods agree	Not in label — unassessed	serious n=543 · 98% clinician	no trial arm names this drug
Bk virus infection	810	37.8 35.0–40.9ROR 38.0 · calibrated p 7e-5 ✓	28.8 EB05 27.2 · IC025 +4.7 3/3 methods agree	Not in label — unassessed	serious n=808 · ♀ 31% (drug 55%) · 96% clinician	no trial arm names this drug
Secondary immunodeficiency	283	36.8 32.2–42.1ROR 36.9 · calibrated p 9e-5 ✓	28.2 EB05 25.5 · IC025 +4.6 3/3 methods agree	Labeled (related wording) related wording	serious n=283 · ♀ 100% (drug 55%)	no trial arm names this drug
Chronic graft versus host disease in skin	213	36.2 31.0–42.2ROR 36.2 · calibrated p 1e-4 ✓	27.8 EB05 24.8 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=213 · 100% clinician	no trial arm names this drug
B-cell type acute leukaemia	167	35.9 30.2–42.7ROR 36.0 · calibrated p 1e-4 ✓	27.6 EB05 24.3 · IC025 +4.4 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=167 · 95% clinician	no trial arm names this drug
Complications of bone marrow transplant	83	34.8 27.2–44.5ROR 34.8 · calibrated p 1e-4 ✓	26.9 EB05 22.4 · IC025 +4.2 3/3 methods agree	Labeled (related wording) related wording	serious n=82	no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

Concept	Reports	PRR 95% CI	Reading
Neutropenia / agranulocytosis	27,115	14.514.4–14.7	signal
Opportunistic infection	6,685	6.16.0–6.2	signal
Thrombocytopenia	9,657	5.45.3–5.5	signal
Interstitial lung disease	3,391	4.34.2–4.5	signal
Anaemia	8,615	3.53.4–3.6	signal
Serious infection	19,607	3.13.0–3.1	signal
Liver injury	6,336	2.52.5–2.6	signal
Heart failure	3,725	2.52.4–2.6	signal
Hyponatraemia	1,565	2.32.2–2.5	signal
Osteonecrosis	1,025	2.12.0–2.3	signal
Kidney injury	7,273	1.91.9–2.0	raised
Venous thromboembolism	3,415	1.91.8–2.0	raised
Arrhythmia / qt	2,355	1.51.4–1.5	raised
Pancreatitis	880	1.31.2–1.4	raised
Gi bleeding	1,749	1.11.1–1.2	raised
Seizure	1,838	1.11.1–1.2	raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Cyclophosphamide For only as a background or rescue medication (NCT02883049, NCT00103285); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Off label use (used outside approved label)	16,346	2.3 2.2–2.3ROR 2.4 · calibrated p 0.858	2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 1.9 · serious PRR 2.4 · 94% clinician	no trial arm names this drug
Febrile neutropenia	14,529	33.3 32.7–33.9ROR 36.2 · calibrated p 9e-5 ✓	26.1 EB05 25.8 · IC025 +4.7 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 23.3 · serious PRR 15.6 · 96% clinician	no trial arm names this drug
Neutropenia (low neutrophils (infection-fighting cells))	10,580	10.0 9.8–10.2ROR 10.6 · calibrated p 0.026 ✓	9.3 EB05 9.2 · IC025 +3.2 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 7.4 · serious PRR 5.7 · 95% clinician	no trial arm names this drug
Drug ineffective (drug did not work)	10,573	1.0 0.9–1.0ROR 1.0 · calibrated p 0.277	1.0 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC	Reporting / coding artifact	age-adj. PRR 1.2 · serious PRR 1.6 · 95% clinician	no trial arm names this drug
Pyrexia (fever)	9,242	3.2 3.2–3.3ROR 3.4 · calibrated p 0.519	3.2 EB05 3.1 · IC025 +1.6 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.6 · serious PRR 2.4 · 92% clinician	no trial arm names this drug
Disease progression	8,096	8.7 8.5–8.9ROR 9.1 · calibrated p 0.044 ✓	8.2 EB05 8.0 · IC025 +3.0 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 7.1 · serious PRR 5.5 · 96% clinician	no trial arm names this drug
Pneumonia (lung infection)	6,667	2.5 2.4–2.5ROR 2.5 · calibrated p 0.793	2.5 EB05 2.4 · IC025 +1.3 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.2 · serious PRR 1.5 · 94% clinician	no trial arm names this drug
Thrombocytopenia (low platelets)	6,523	7.3 7.2–7.5ROR 7.6 · calibrated p 0.078	7.0 EB05 6.8 · IC025 +2.8 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 5.5 · serious PRR 4.3 · 96% clinician	no trial arm names this drug
Product use in unapproved indication	6,513	3.2 3.2–3.3ROR 3.3 · calibrated p 0.530	3.2 EB05 3.1 · IC025 +1.6 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 2.9 · serious PRR 4.0 · 95% clinician	no trial arm names this drug
Nausea	6,251	0.9 0.9–1.0ROR 0.9 · calibrated p 0.269	0.9 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC	Labeled adverse reaction exact term	age-adj. PRR 0.8 · serious PRR 1.0	no trial arm names this drug
Anaemia (low red blood cells)	6,149	3.9 3.8–4.0ROR 4.0 · calibrated p 0.370	3.8 EB05 3.8 · IC025 +1.9 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 3.2 · serious PRR 2.5 · 94% clinician	no trial arm names this drug
Sepsis (blood infection)	5,729	6.4 6.2–6.6ROR 6.6 · calibrated p 0.117	6.1 EB05 6.0 · IC025 +2.6 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 5.0 · serious PRR 3.7 · 94% clinician	no trial arm names this drug
Diarrhoea (diarrhea)	5,488	1.0 1.0–1.0ROR 1.0 · calibrated p 0.318	1.0 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC	Labeled adverse reaction exact term	age-adj. PRR 0.9 · serious PRR 1.0 · 91% clinician	no trial arm names this drug
Death	5,221	0.7 0.7–0.7ROR 0.7 · calibrated p 0.136	0.7 EB05 0.7 · IC025 -0.5 PRR-only: not supported by EBGM or IC	Outcome field, not a reaction	age-adj. PRR 0.6 · serious PRR 0.4 · 91% clinician	no trial arm names this drug
Vomiting	4,910	1.3 1.2–1.3ROR 1.3 · calibrated p 0.479	1.2 EB05 1.2 · IC025 +0.3	Labeled adverse reaction exact term	age-adj. PRR 1.0 · serious PRR 1.1 · 92% clinician	no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Thymus hypoplasia — n=140, PRR 544.0
Human bocavirus infection — n=116, PRR 187.8
Engraftment syndrome — n=231, PRR 77.2
Primary amyloidosis — n=92, PRR 67.9
Encephalitis cytomegalovirus — n=155, PRR 66.4
Acute graft versus host disease in skin — n=871, PRR 54.8
Acute graft versus host disease — n=1,426, PRR 53.1
Engraft failure — n=88, PRR 52.9
Congenital aplasia — n=85, PRR 49.3
Chronic graft versus host disease — n=1,056, PRR 48.5

✓ A hand-written Bradford Hill causality assessment exists for this drug: Cyclophosphamide ↔ Haemorrhagic cystitis.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Cyclophosphamide For?

In FDA FAERS, the most frequently co-reported reaction terms for Cyclophosphamide For are febrile neutropenia, neutropenia, pyrexia, pneumonia, thrombocytopenia, nausea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Cyclophosphamide For have an FDA boxed warning?

No. The FDA label retrieved for Cyclophosphamide For has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Cyclophosphamide For causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 6fde2705-a2d8-4d48-9618-b9d99d051373, effective 20250103; matched on openfda.generic_name.exact:"CYCLOPHOSPHAMIDE FOR INJECTION")
PubChem CID 2907 description (ChEBI)
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 1,367 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath
ClinicalTrials.gov API v2 (query CYCLOPHOSPHAMIDE FOR, results-bearing studies sorted by enrollment)

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.